VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MRNA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MRNAModerna, Inc.
$206.80$82.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MRNA
  4. Financial Ratios

Moderna, Inc. (MRNA) Financial Ratios

Latest Ratios: P/E Ratio -31.9x · EV/EBITDA N/A · ROE -28.9%. (2016–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MRNA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$82.1B$11.5B$16.0B$38.0B$74.7B$109.5B$39.8B$6.5B$5.0B——
Enterprise Value$81.4B$10.8B$14.8B$36.3B$72.7B$103.5B$37.5B$6.4B$4.4B——
P/E Ratio →-31.88———8.948.98—————
P/S Ratio32.505.904.995.553.966.1749.59107.4737.17——
P/B Ratio9.301.331.462.743.917.7415.565.513.28——
P/FCF————16.318.2120.33————
P/OCF————15.008.0419.65————

P/E links to full P/E history page with 30-year chart

MRNA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—5.554.625.303.855.8446.62105.7532.55——
EV / EBITDA————7.447.65—————
EV / EBIT————7.577.78—————
EV / FCF————15.877.7619.11————

MRNA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin55.3%55.3%54.2%31.5%71.3%85.2%95.1%48.5%81.6%90.0%86.1%
Operating Margin-158.1%-158.1%-123.3%-61.9%49.9%75.0%-95.0%-906.4%-347.1%-130.9%-206.4%
Net Profit Margin-145.2%-145.2%-111.3%-68.8%44.3%68.8%-93.0%-853.7%-284.8%-124.3%-199.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-28.9%-28.9%-28.8%-28.6%50.3%146.1%-40.0%-38.0%-35.7%-34.9%-25.7%
ROA-21.3%-21.3%-21.9%-21.3%33.1%76.2%-16.7%-28.9%-25.3%-20.5%-15.3%
ROIC-26.1%-26.1%-27.0%-21.7%55.8%237.8%-91.9%-41.4%-49.8%-30.8%-20.9%
ROCE-27.6%-27.6%-28.9%-23.3%51.7%143.8%-34.7%-34.3%-35.6%-25.1%-17.8%

MRNA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.220.220.070.090.060.060.090.110.020.030.01
Debt / EBITDA————0.120.07—————
Net Debt / Equity—-0.08-0.11-0.12-0.10-0.42-0.93-0.09-0.41-0.19-0.04
Net Debt / EBITDA————-0.21-0.44—————
Debt / FCF————-0.44-0.44-1.22———-1.12
Interest Coverage-276.80-276.80-149.29-102.74331.17739.06-74.31-76.85-141.12-1938.36—

Net cash position: cash ($2.6B) exceeds total debt ($1.9B)

MRNA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.293.293.673.422.731.761.437.897.024.096.68
Quick Ratio3.223.223.623.362.541.601.427.897.024.096.68
Cash Ratio2.922.923.182.852.011.181.057.716.833.956.50
Asset Turnover—0.160.230.370.730.720.110.040.070.190.08
Inventory Turnover5.675.6712.5123.235.711.820.83————
Days Sales Outstanding—53.3267.5557.6232.5868.39639.6998.8082.6532.6460.45

MRNA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield————11.2%11.1%—————
FCF Yield————6.1%12.2%4.9%————
Buyback Yield0.0%0.0%0.0%3.0%4.5%0.8%0.0%0.0%0.2%——
Total Shareholder Yield0.0%0.0%0.0%3.0%4.5%0.8%0.0%0.0%0.2%——
Shares Outstanding—$389M$384M$382M$416M$431M$381M$331M$329M$376M$64M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Commercial revenue volatility and cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Price Platform Optionality

Based on reported figures, Moderna trades at a price-to-sales ratio of 42.27 and a price-to-book of 12.10 despite a trailing P/E of -41.47, indicating the market is pricing future platform value rather than current earnings power.

With trailing earnings negative, the P/E multiple is not meaningful as a valuation anchor, and the 42.27 P/S ratio implies investors are capitalizing a revenue base that has contracted roughly 39% on a trailing basis. The 12.10 price-to-book multiple, against equity that has fallen from $11.9B to $6.8B, suggests the premium rests on the optionality of the mRNA library and pipeline rather than on tangible balance sheet value. Investors should monitor whether pipeline catalysts such as intismeran can justify this premium before the cash balance is further depleted.

Quarterly Rebound Fails to Repair Trailing Losses

As reported in quarterly filings, Moderna's Q3 2026 net margin of 12.3% contrasts with a trailing net margin of -145.2% and an operating margin of -158.1%, leaving the one-quarter improvement unconfirmed as a sustained trend.

The gross margin swung from 15.9% in 2025Q1 to 75.8% in 2026Q3, which points to a revenue base highly sensitive to volume and inventory timing rather than stable unit economics. A single quarter of positive net margin, set against fixed R&D and manufacturing costs that remain elevated, may reflect a seasonal or one-time benefit rather than structural recovery. Earnings quality should be assessed after stripping out milestone and collaboration revenue before inferring a durable inflection.

Debt Step-Up Erodes Coverage Cushion

Based on reported balance sheet figures, Moderna's debt-to-equity ratio rose from 0.19 to 0.61 within a single quarter, while the debt-to-EBITDA ratio of 21.11 signals thin earnings coverage of obligations.

The jump in leverage from $1.3B to $4.2B of total debt occurred while equity was contracting, which suggests the balance sheet is being financed rather than rebuilt by operations. A debt-to-EBITDA of 21.11 and an interest coverage ratio that is not meaningfully positive indicate limited earnings capacity to service the new obligations. The terms, maturity profile, and any covenant conditions of this borrowing are not disclosed in the provided data and warrant further investigation.

Current Ratio Masks Thinning Cash Runway

According to the reported balance sheet, Moderna's current ratio of 3.62 and quick ratio of 3.47 appear comfortable, yet cash declined from $2.6B to $1.2B against a free cash flow margin of -122.3%.

High current and quick ratios are driven largely by the cash and receivable base, which is being consumed at a rapid pace by operating and capital needs. The gap between the strong ratio readings and the shrinking absolute cash position suggests the liquidity cushion may be less durable than the headline metrics imply. Under a prolonged period of negative free cash flow, the balance could compress meaningfully, so investors should monitor quarterly cash burn against available liquidity.

Working Capital Ratios Misread Business Model

The current ratio is most commonly misapplied to Moderna because it treats pandemic-era inventory and receivables as stable liquidity, obscuring write-down and obsolescence risk in a shrinking vaccine demand base.

For a company whose revenue was historically tied to government advance purchase agreements, the current ratio can overstate liquidity when inventory is at risk of write-down, as reflected in the days inventory outstanding of 86 days and the high DIO in prior periods. A better lens is free cash flow runway, measured as cash divided by quarterly cash burn, adjusted for non-cash inventory charges. This alternative captures the real survival horizon that the current ratio fails to reflect.

Download Financial Ratios Data

Includes 30+ ratios · 10 years · Updated daily

Consensus & Technical Research Suite
Open MRNA Terminal

MRNA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MRNA — Frequently Asked Questions

Quick answers to the most common questions about buying MRNA stock.

What is Moderna, Inc.'s P/E ratio?

Moderna, Inc.'s current P/E ratio is -31.9x. The historical average is 9.0x.

What is Moderna, Inc.'s ROE?

Moderna, Inc.'s return on equity (ROE) is -28.9%. The historical average is -6.4%.

Is MRNA stock overvalued?

Based on historical data, Moderna, Inc. is trading at a P/E of -31.9x. Compare with industry peers and growth rates for a complete picture.

What are Moderna, Inc.'s profit margins?

Moderna, Inc. has 55.3% gross margin and -158.1% operating margin.